Showing results (421-430 of 505) with videos related to

Sort By:
Pageof 51
Deutsche Medizinische Wochenschrift (1946)|October 8, 2009
["TRECID", TNFalpha related chronic inflammatory diseases - a new multiple diseases bridging concept]U Müller-Ladner, R Alten, A Heiligenhaus, et al.
Alimentary Pharmacology & Therapeutics|January 16, 2009
Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitisC Pena-Rossi, S Schreiber, G Golubovic, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 2, 2009
Tuberculosis retreatment category predicts resistance in hospitalized retreatment patients in a high HIV prevalence areaY S Schreiber, A F Herrera, D Wilson, et al.
Gastroenterology|July 6, 2004
Successful growth and characterization of mouse pancreatic ductal cells: functional properties of the Ki-RAS(G12V) oncogeneFranz S Schreiber, Therese B Deramaudt, Thomas B Brunner, et al.
Journal of Crohn'S & Colitis|June 19, 2012
Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's diseaseS Schreiber, W Reinisch, J F Colombel, et al.
Gastroenterology|December 13, 2000
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study GroupR N Fedorak, A Gangl, C O Elson, et al.
Clinical and Experimental Immunology|November 11, 2014
The wingless-related integration site-5a/secreted frizzled-related protein-5 system is dysregulated in human sepsisD M Schulte, D Kragelund, N Müller, et al.
The European Respiratory Journal|July 24, 2010
Association of inflammatory bowel disease risk loci with sarcoidosis, and its acute and chronic subphenotypesA Fischer, M Nothnagel, A Franke, et al.
Neuroscience|May 1, 2007
The absence of endogenous beta-endorphin selectively blocks phosphorylation and desensitization of mu opioid receptors following partial sciatic nerve ligationM Petraschka, S Li, T L Gilbert, et al.
Alimentary Pharmacology & Therapeutics|August 23, 2014
Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 studyW J Sandborn, S D Lee, C Randall, et al.
Pageof 51